RIGEL PHARMACEUTICALS, INC. (RIGL) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Win.
47/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 10 wins, 2 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinRIGL / S&P 44.67% / 15.20% |
LoseRIGL / S&P 3.31% / 15.00% |
WinRIGL / S&P 211.44% / 50.40% |
| 2026-Q12/3 |
LoseRIGL / S&P -36.87% / -4.33% |
WinRIGL / S&P 47.61% / 11.30% |
WinRIGL / S&P 826.92% / 27.70% |
| 2025-Q43/3 |
WinRIGL / S&P 51.18% / 2.65% |
WinRIGL / S&P 64.15% / 9.00% |
WinRIGL / S&P 1886.73% / 13.40% |
| 2025-Q33/3 |
WinRIGL / S&P 51.25% / 8.12% |
WinRIGL / S&P 79.13% / 4.61% |
WinRIGL / S&P 2709.09% / 13.45% |
| 2025-Q21/3 |
LoseRIGL / S&P 4.11% / 10.94% |
WinRIGL / S&P 105.62% / 4.83% |
LoseRIGL / S&P -769.14% / 10.63% |
| 2025-Q12/3 |
WinRIGL / S&P 6.96% / -4.27% |
WinRIGL / S&P 68.74% / 4.98% |
LoseRIGL / S&P -284.07% / 10.57% |
| 2024-Q42/3 |
WinRIGL / S&P 3.96% / 2.41% |
WinRIGL / S&P 53.38% / 5.25% |
LoseRIGL / S&P -232.43% / 6.15% |
| 2024-Q32/3 |
WinRIGL / S&P 96.84% / 5.89% |
WinRIGL / S&P 18.97% / 5.89% |
LoseRIGL / S&P -105.67% / 6.11% |
| 2024-Q20/3 |
LoseRIGL / S&P -44.46% / 4.28% |
LoseRIGL / S&P 2.89% / 5.38% |
LoseRIGL / S&P -77.87% / 5.12% |
| 2024-Q10/3 |
LoseRIGL / S&P 2.07% / 10.56% |
LoseRIGL / S&P -7.12% / 5.71% |
LoseRIGL / S&P -66.37% / 5.59% |
| 2023-Q41/3 |
WinRIGL / S&P 34.26% / 11.69% |
LoseRIGL / S&P -2.79% / 6.81% |
LoseRIGL / S&P -78.49% / 7.78% |
| 2023-Q32/3 |
LoseRIGL / S&P -16.28% / -3.27% |
WinRIGL / S&P 48.11% / 7.52% |
WinRIGL / S&P 691.84% / -5.03% |
| 2023-Q22/3 |
LoseRIGL / S&P -2.27% / 8.74% |
WinRIGL / S&P 43.09% / 9.50% |
WinRIGL / S&P 632.00% / -8.57% |
| 2023-Q12/3 |
LoseRIGL / S&P -12.00% / 7.50% |
WinRIGL / S&P 52.53% / 10.77% |
WinRIGL / S&P 572.00% / -15.69% |
| 2022-Q42/3 |
WinRIGL / S&P 27.12% / 7.56% |
LoseRIGL / S&P -19.43% / 11.88% |
WinRIGL / S&P 2766.67% / -17.99% |
| 2022-Q32/3 |
WinRIGL / S&P 4.42% / -4.88% |
LoseRIGL / S&P -39.32% / 13.47% |
WinRIGL / S&P 390.00% / -1.41% |
| 2022-Q21/3 |
LoseRIGL / S&P -62.21% / -16.10% |
LoseRIGL / S&P -38.59% / 13.71% |
WinRIGL / S&P 733.33% / 11.04% |
| 2022-Q12/3 |
WinRIGL / S&P 12.83% / -4.60% |
LoseRIGL / S&P -36.54% / 15.97% |
WinRIGL / S&P 525.00% / 42.23% |
| 2021-Q41/3 |
LoseRIGL / S&P -27.00% / 11.03% |
WinRIGL / S&P 37.39% / 15.00% |
LoseRIGL / S&P -29.41% / 96.40% |
| 2021-Q31/3 |
LoseRIGL / S&P -16.36% / 0.58% |
WinRIGL / S&P 39.51% / 10.77% |
LoseRIGL / S&P RIGL unavailable / 69.42% |
| 2021-Q22/3 |
WinRIGL / S&P 26.90% / 8.55% |
WinRIGL / S&P 33.40% / 6.58% |
LoseRIGL / S&P RIGL unavailable / 51.81% |
| 2021-Q11/3 |
LoseRIGL / S&P -2.29% / 6.17% |
WinRIGL / S&P 30.71% / -1.06% |
LoseRIGL / S&P RIGL unavailable / 7.39% |
| 2020-Q42/3 |
WinRIGL / S&P 45.83% / 12.15% |
WinRIGL / S&P 83.21% / -3.72% |
LoseRIGL / S&P RIGL unavailable / -33.42% |
| 2020-Q32/3 |
WinRIGL / S&P 31.15% / 8.93% |
WinRIGL / S&P 29.15% / -2.04% |
LoseRIGL / S&P RIGL unavailable / -27.10% |
| 2020-Q21/3 |
LoseRIGL / S&P 17.31% / 20.54% |
WinRIGL / S&P 64.31% / -0.46% |
LoseRIGL / S&P RIGL unavailable / -27.11% |
| 2020-Q11/3 |
LoseRIGL / S&P -27.10% / -19.60% |
WinRIGL / S&P 79.27% / 3.47% |
LoseRIGL / S&P RIGL unavailable / -14.75% |
| 2019-Q41/3 |
WinRIGL / S&P 14.44% / 9.07% |
LoseRIGL / S&P RIGL unavailable / 5.36% |
LoseRIGL / S&P RIGL unavailable / 2.99% |
| 2019-Q30/3 |
LoseRIGL / S&P -28.35% / 1.70% |
LoseRIGL / S&P RIGL unavailable / 5.02% |
LoseRIGL / S&P RIGL unavailable / 0.21% |
| 2019-Q20/3 |
LoseRIGL / S&P 1.56% / 4.30% |
LoseRIGL / S&P RIGL unavailable / 6.64% |
LoseRIGL / S&P RIGL unavailable / 8.65% |
| 2019-Q10/3 |
LoseRIGL / S&P 11.74% / 13.65% |
LoseRIGL / S&P RIGL unavailable / 8.12% |
LoseRIGL / S&P RIGL unavailable / 14.29% |
| 2018-Q40/3 |
LoseRIGL / S&P -28.35% / -13.52% |
LoseRIGL / S&P RIGL unavailable / 9.05% |
LoseRIGL / S&P RIGL unavailable / 18.23% |
| 2018-Q31/3 |
WinRIGL / S&P 13.43% / 7.71% |
LoseRIGL / S&P RIGL unavailable / 10.21% |
LoseRIGL / S&P RIGL unavailable / 19.06% |
| 2018-Q20/3 |
LoseRIGL / S&P -20.06% / 3.43% |
LoseRIGL / S&P RIGL unavailable / 9.03% |
LoseRIGL / S&P RIGL unavailable / 14.46% |
| 2018-Q10/3 |
LoseRIGL / S&P -8.76% / -0.76% |
LoseRIGL / S&P RIGL unavailable / 7.68% |
LoseRIGL / S&P RIGL unavailable / 12.46% |
| 2017-Q41/3 |
WinRIGL / S&P 52.76% / 6.64% |
LoseRIGL / S&P RIGL unavailable / 7.03% |
LoseRIGL / S&P RIGL unavailable / 13.82% |
| 2017-Q30/3 |
LoseRIGL / S&P -6.96% / 4.48% |
LoseRIGL / S&P RIGL unavailable / 5.68% |
LoseRIGL / S&P RIGL unavailable / 17.57% |
| 2017-Q20/3 |
LoseRIGL / S&P -17.52% / 3.09% |
LoseRIGL / S&P RIGL unavailable / 4.83% |
LoseRIGL / S&P RIGL unavailable / 17.74% |
| 2017-Q11/3 |
WinRIGL / S&P 39.08% / 6.07% |
LoseRIGL / S&P RIGL unavailable / 3.67% |
LoseRIGL / S&P RIGL unavailable / 13.32% |
| 2016-Q40/3 |
LoseRIGL / S&P -35.15% / 3.82% |
LoseRIGL / S&P RIGL unavailable / 2.09% |
LoseRIGL / S&P RIGL unavailable / 7.05% |
| 2016-Q31/3 |
WinRIGL / S&P 64.57% / 3.85% |
LoseRIGL / S&P RIGL unavailable / 0.20% |
LoseRIGL / S&P RIGL unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | RIGL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 20.62% | 20.78% |
| Annualized return | 20.62% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | RIGL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 14.01% | 83.14% |
| Annualized return | 2.66% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | RIGL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 35.83% | 319.30% |
| Annualized return | 3.11% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |